Alectinib

Overview

Alectinib is an oral medication used for the treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). It is a highly selective ALK inhibitor that improves progression-free survival in patients with advanced ALK-positive NSCLC.

API suppliers (1)

Suppliers of Alectinib backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• FRESENIUS KABI ONCOLOGY LTD

Patent & exclusivity (US)

Per the FDA Orange Book (1 approved US product), the latest listed US patent on Alectinib expires 23 Apr 2035 and exclusivity 17 Apr 2031. Generic API sourcing typically opens up once these lapse.

Therapeutic areas